Related Experiment Video
Updated: Jun 5, 2026
10:46
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
FK506 binding proteins as targets in anticancer therapy
Simona Romano1, Annalaura Di Pace, Antonio Sorrentino
1Department of Biochemistry and Medical Biotechnology, University Federico II, Naples, Italy. romano@dbbm.unina.it
Anti-Cancer Agents in Medicinal Chemistry
|December 25, 2010
Summary
FK506 binding proteins (FKBPs) are key targets for cancer therapy. Inhibiting FKBPs promotes apoptosis and overcomes drug resistance in various cancers, offering new therapeutic strategies.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- FK506 binding proteins (FKBPs) are intracellular ligands for immunosuppressants FK506 and rapamycin.
- Immunosuppressants show promise as anticancer agents, with rapamycin derivatives used successfully in various tumors.
- FKBP-drug complexes modulate signaling pathways like mTOR and calcineurin, crucial for T-cell activation and cancer growth.
Purpose of the Study:
- To review the role of FKBP members in apoptosis regulation.
- To summarize data on the antitumor effects of selective FKBP targeting.
- To explore FKBPs as potential targets for novel cancer therapies.
Main Methods:
- Literature review of studies on FKBP function in cancer.
- Analysis of research on FKBP targeting and apoptosis induction.
- Examination of FKBP involvement in key cancer signaling pathways (mTOR, calcineurin).
Main Results:
- Targeting FKBP12 promotes apoptosis in chronic lymphocytic leukemia.
- FKBP38 knockdown sensitizes hepatoma cells to apoptosis.
- FKBP51 silencing overcomes apoptosis resistance in leukemia, prostate cancer, melanoma, and glioma.
- FKBP inhibition represents a mechanism for the anticancer activity of immunosuppressants.
Conclusions:
- Selective targeting of FKBPs demonstrates significant antitumor effects.
- FKBPs play a critical role in controlling apoptosis and overcoming drug resistance.
- Targeting FKBPs offers a promising strategy for developing new anticancer therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...